Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Research and Markets
DUBLIN, Ireland, December 23, 2013 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/blkvt9/north_american) has announced the addition of the "2013 Report on the North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 in Canada is, however, a major threat for manufacturers.
The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects; radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.
Key Topics Covered:
2 Executive Summary
3 Market Overview
4 North American Radiopharmaceuticals Market, By Isotope
5 North American Radiopharmaceuticals Market, By Application/Indications
6 North American Enriched Stable Isotopes Market
7 Geographic Analysis
8 Competitive Landscape
9 Company Profiles
For more information visit http://www.researchandmarkets.com/research/blkvt9/north_american
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
©2012 PR Newswire. All Rights Reserved.